Hodgkin lymphoma is a lymphoid malignancy characterized by abnormal Reed-Sternberg cells in an inflammatory background. It often presents with painless lymphadenopathy and may include systemic B symptoms. With modern therapy, cure rates are high in many patients, especially at earlier stages.
The FDA has approved nivolumab with chemotherapy for pediatric and adult Hodgkin lymphoma patients aged 12+, based on clinical trial data showing improved survival. Separately, the agency cleared investigational new drug applications for FG001 for brain cancer surgery visualization and FRF-001 gene therapy for FOXG1 syndrome, allowing both to proceed to clinical trials.
New research examines both the long-term biological aging effects of childhood cancer treatments and proposes alternative treatment sequencing strategies to prevent tumor resistance and improve cure rates.
The FDA approved KEYTRUDA and its subcutaneous QLEX formulation for platinum-resistant ovarian cancer, marking the first PD-1 inhibitor cleared for this patient population based on Phase 3 results.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07576725 |
Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial |
NOT_YET_RECRUITING | PHASE2 |
| NCT07566377 |
Cord Blood Transplantation in Children and Young Adults With Blood Cancer |
RECRUITING | PHASE2 |
| NCT07551583 |
Phase 2 Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL |
NOT_YET_RECRUITING | PHASE2 |
| NCT07514819 |
Integration of Adaptive Proton Therapy in Pediatric Solid Tumors and Hodgkin's Lymphoma |
NOT_YET_RECRUITING | NA |
| NCT07451054 |
CD45BE-HSPC + CART-45 Cells |
NOT_YET_RECRUITING | PHASE1 |
| NCT07444632 |
Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies |
NOT_YET_RECRUITING | PHASE1 |
| NCT07374068 |
Prognostic Model of Elderly Hodgkin Lymphoma in China |
ACTIVE_NOT_RECRUITING | |
| NCT07285044 |
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas |
RECRUITING | PHASE2 |
| NCT07270679 |
Genetic Markers of Susceptibility to Chemotherapy-induced Ovarian Damage in Cancer Patients Undergoing Ovarian Biopsy for Cryopreservation. |
RECRUITING | |
| NCT07259304 |
Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors |
RECRUITING |
